Today: 9 June 2026
Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’
15 January 2026
1 min read

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’

NEW YORK, Jan 15, 2026, 05:43 EST — Premarket

Broadcom Inc (AVGO) shares fell roughly 4.2% to $339.89 in premarket trading Thursday, following reports that China has instructed local companies to halt use of certain foreign cybersecurity software, including VMware, which Broadcom owns.

This report hits Broadcom’s software business, not just its chip division. It comes quickly too, as U.S.-China tech tensions stretch beyond export controls into the core infrastructure of corporate networks.

Traders are digesting new sell-side reports alongside a debt refinancing move Broadcom revealed in an SEC filing. Not exactly the recipe for a steady open.

Chinese authorities have ordered companies to halt use of cybersecurity software from over a dozen U.S. and Israeli firms, citing national security risks, according to three sources who spoke to Reuters. The U.S. companies named include Broadcom-owned VMware, Palo Alto Networks, and Fortinet. Reuters was unable to determine how many firms received the directive. Orca Security CEO Gil Geron, whose company was also reportedly targeted, called the ban “a step in the wrong direction.” Reuters

Broadcom dropped 4.15% during Wednesday’s regular session, underperforming as the tech selloff dragged the Nasdaq down and hit several chip stocks. Nvidia slipped 1.44%, according to MarketWatch data.

Uncertainty around China returned to the headlines this week. On Thursday, Reuters reported that China is working on new rules to limit how many advanced AI chips, including Nvidia’s H200, domestic companies can bring in. The story cites a report from Nikkei Asia.

Broadcom disclosed in an SEC filing that it has struck an underwriting deal to issue $4.5 billion in senior notes—unsecured corporate bonds—spanning four maturities. Coupon rates range from 4.300% due 2031 up to 5.700% due 2056. The company plans to deploy the net proceeds for general corporate needs and to pay down debt. It has also initiated redemption notices for several outstanding note series, including those linked to VMware.

RBC Capital’s Srini Pajjuri kicked off coverage of Broadcom with a Sector Perform rating and set a $370 price target, highlighting ongoing concerns about margins and the staying power of big AI-related contracts. He noted that TPUs — tensor processing units, specialized AI chips for data centers — show near-term strength, but called the Anthropic ramp a “question mark” and described the OpenAI opportunity as “less clear.” TipRanks

The downside is straightforward: a broad, lasting China directive could push VMware’s customers toward local options, hurting renewals and stalling new business. But if the notice ends up narrow, patchily enforced, or gets rolled back, attention will shift back to AI demand and refinancing details.

Investors are gearing up for any updates from Broadcom, Chinese regulators, or other firms mentioned in the report. All eyes will be on whether the software blacklist expands beyond cybersecurity. The bond market is focused on upcoming redemption dates: Jan. 17, Jan. 22, and Feb. 6.

Stock Market Today

  • Regentis Biomaterials Plans European Surgeon Training for GelrinC Implant
    June 9, 2026, 9:53 AM EDT. Regentis Biomaterials' shares edged down to $1.28 ahead of the New York open as the company outlined its European launch strategy for GelrinC, a knee cartilage repair hydrogel implant. The Israeli regenerative-medicine firm will begin surgeon training in Q3 at Humanitas Research Hospital in Milan, marking a key step between CE Mark regulatory clearance and commercial use in Europe. GelrinC's "off-the-shelf" design contrasts with custom-grown products, aiming to ease adoption. However, key uncertainties remain around FDA approval in the U.S., clinical trial outcomes, market acceptance, reimbursement, and competition from established implants by Smith+Nephew and Vericel. Regentis raised $10 million at its December 2025 IPO to fund pivotal U.S. trials and PMA submission. CEO Dr. Ehud Geller called training "critical" for physician adoption ahead of broader rollout.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown
Previous Story

NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Next Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Go toTop